spot_img
Friday, August 12, 2022
More
    HomeHealthBristol CEO Giovanni Caforio on new drug launches, acquisitions in 2022

    Bristol CEO Giovanni Caforio on new drug launches, acquisitions in 2022

    -



    Later this 12 months, Bristol Myers Squibb will start to lose billions of {dollars} in income when generic variations of its top-selling most cancers drug Revlimid develop into accessible. However with six current drug launches and one other three medication heading for the market this 12 months, Bristol expects to offset the misplaced Revlimid income and proceed to develop by the top of the last decade.

    Recent off a presentation on the J.P. Morgan Healthcare Convention, Bristol CEO Giovanni Caforio sat down with STAT final week to debate his firm’s outlook and plans for extra enterprise improvement, together with acquisitions.

    Unlock this text by subscribing to STAT+ and revel in your first 30 days free!

    GET STARTED





    Source link

    Related articles

    Stay Connected

    0FansLike
    0FollowersFollow
    3,433FollowersFollow
    0SubscribersSubscribe
    spot_img

    Latest posts